1. The robust performance of carcinoembryonic antigen levels after adjuvant chemotherapy for the recurrence risk stratification in patients with colorectal cancer
- Author
-
Tsuyoshi Ozawa, Keiji Matsuda, Yoshihisa Fukushima, Yojiro Hashiguchi, Soichiro Ishihara, Tamuro Hayama, Ryu Shimada, and Keijiro Nozawa
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Multivariate analysis ,Colorectal cancer ,Adjuvant chemotherapy ,medicine.medical_treatment ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Carcinoembryonic antigen ,Internal medicine ,Biomarkers, Tumor ,Humans ,Medicine ,Stage (cooking) ,neoplasms ,Aged ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,biology ,business.industry ,General Medicine ,medicine.disease ,Survival Analysis ,digestive system diseases ,Confidence interval ,Carcinoembryonic Antigen ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,biology.protein ,Biomarker (medicine) ,Female ,030211 gastroenterology & hepatology ,Surgery ,Neoplasm Recurrence, Local ,Colorectal Neoplasms ,business - Abstract
Background and objectives Most guidelines of colorectal cancers (CRCs) recommend evaluating the serum carcinoembryonic antigen (CEA) level during postoperative surveillance to detect tumor recurrence, which originates from postsurgery residual tumor cells. We hypothesized that the postadjuvant chemotherapy CEA level may be the most accurate biomarker to predict tumor recurrence, and we evaluated the prognostic significance of the postadjuvant chemotherapy CEA level in patients with stage II and III CRCs. Patients and methods We retrospectively analyzed the cases of 150 Stage II-III CRC patients who had undergone curative surgery and adjuvant chemotherapy. Preoperative, postoperative, and postadjuvant chemotherapy CEA levels were evaluated, and their associations with recurrence-free survival (RFS) were assessed. Results The Kaplan-Meier curves showed that a high preoperative CEA level, high postoperative CEA, and high postadjuvant chemotherapy CEA were associated with poor RFS (p = .001, .0001, and .001, respectively). The multivariate analysis demonstrated that high postadjuvant chemotherapy CEA was an independent factor for poor RFS (HR 2.55, 95% confidence interval: 1.08-6.05, p = .033), whereas high preoperative and postoperative CEA levels were not. Conclusions The serum levels of postadjuvant chemotherapy CEA were a strong prognostic biomarker in patients with Stage II-III CRCs who had undergone surgery followed by adjuvant chemotherapy.
- Published
- 2021
- Full Text
- View/download PDF